Compression Behaviour of Botanical Powder APIs in Oral Tablet Manufacture

Huashi Zhixie Powder Veterinary Grade API is not a single-molecule active but a multi-component fibrous matrix whose compression behaviour is governed by residual moisture, fibre length distribution, and water-soluble polysaccharide content. The incoming powder often presents a loss on drying above 8.0% and an angle of repose greater than 40°, which prevents direct compression on a rotary tablet press without pre-milling, moisture adjustment, and granulation. The powder is first milled through a 0.5 mm screen, then dry-blended with microcrystalline cellulose q.s. to 100% w/w, sodium starch glycolate at 2.0–5.0% w/w, and colloidal silicon dioxide at 0.2–0.5% w/w in a twin-shell blender at 60% fill for 10–15 min. A povidone K30 binder solution is sprayed into a high-shear granulator at 1.0–3.0% w/w of the dry mass, with impeller speed held at 150–200 rpm and chopper speed at 1500 rpm. The granulation endpoint is monitored by mixer torque rheometry; botanical granulations of this general type typically reach endpoint between 1.5 N·m and 2.5 N·m at development scale, although published data for this specific API configuration is limited and the endpoint must be confirmed experimentally. Drying is conducted in a fluid bed dryer with inlet air not exceeding 60°C because volatile marker fractions in the botanical matrix degrade under higher thermal load. Final granule loss on drying is controlled at 2.0–3.5%. Magnesium stearate is added at 0.5–1.0% w/w for 3 min immediately before compression. Tablets are compressed to hardness 60–90 N; compression beyond 90 N has been associated with capping in fibrous botanical compacts due to elastic recovery after ejection. Content uniformity is evaluated according to USP <905>, and disintegration is assessed by USP <701> in water at 37°C, with a release limit of not more than 15 min. The terminal product is a scored oral tablet intended for individual dosing in piglets, lambs, or calves. Formulation incompatibility exists with strongly alkaline direct-compression fillers such as calcium carbonate; if the surface pH of an uncoated tablet exceeds 8.0, polyphenolic fractions may be destabilized, producing discolouration and loss of marker content. All excipients used in a food-producing animal dosage form must be selected against the authorized veterinary medicinal product file and the target-market regulation, for example Directive 2001/82/EC in the European Union.

Feed mill dilution of the API into a registered medicated premix imposes segregation control, sampling, and carryover constraints not present in pharmaceutical tableting. The botanical fibre fraction has lower tapped density than common feed carriers, and screw conveyor transfer after mixing can separate the API from mineral components if the particle size difference exceeds the acceptable ratio for the carrier system. To reduce this risk, the powder is first pre-blended with a neutral-pH carrier such as ground rice hull or wheat middlings at a carrier-to-API ratio between 5:1 and 10:1 in a paddle mixer. The resulting intermediate is transferred to a ribon mixer operated at 40–70% fill and mixed for 10–15 min after the last ingredient addition. Without a defined pre-blend step, the coefficient of variation for marker content in the finished premix can exceed 10.0% at the planned inclusion rate. Release sampling is performed according to ISO 6497:2002, taking not fewer than 10 random increments; a batch is not released if the coefficient of variation exceeds 5.0%. In the United States, medicated feed labelling and distribution fall under 21 CFR 558.3; in the European Union, medicated feed manufacture must align with Regulation (EU) 2019/4 and the authorized veterinary medicinal product file. The largest source of batch-to-batch variance at production scale is residual moisture in the incoming API above 8.0%, which causes wall adhesion and increases mixer clean-out time. Static charge also rises sharply when relative humidity drops below 30%, producing streaking on the mixer shell and flow obstruction at discharge; grounding lines and controlled humidification are required for reliable operation. When the medicated premix is subsequently pelleted, conditioner temperatures above 80°C may degrade heat-labile aromatic markers; if the product is intended for pelleted feed, post-pelleting addition or a reduced-temperature conditioning step should be evaluated.

When the Powder Is Reconstituted for Drinking-Water Medication

The term solution is a regulatory classification, but the botanical powder is not fully soluble in water; the finished liquid is a filtered extract and fine suspension unless an extraction step is performed. A standard development decoction uses purified water at 90–95°C for 30 min at a 1:10 w/v ratio, followed by passage through a 200-mesh screen and cooling to 25°C before transfer into a stainless steel holding tank. The resulting oral liquid has a pH between 4.5 and 6.5; if the drinking-water line pH falls below 4.0 due to acidified water, polysaccharide precipitation is observed and can clog nipple drinkers. For automatic proportioner dosing, the stock liquid must be filtered again through a 0.15 mm inline strainer before the proportioner inlet, and the in-use holding time should not exceed 12 h at ambient temperature unless preservative efficacy has been demonstrated. Batch documentation should include USP <51> antimicrobial effectiveness testing if the liquid is packaged rather than freshly mixed, and the extraction ratio must be supported by marker assay. The terminal product is an oral liquid for mass medication of poultry or swine via drinking water, packed in HDPE jerry cans or flexible bag-in-box systems. Microbial growth is the main stability failure; without preservation, a decoction stored above 30°C can show visible turbidity within 6 h to 12 h. If a preserved product is required, the preservative selection must avoid known incompatibilities with tannin-rich botanical extracts, for which benzalkonium chloride can form insoluble complexes at concentrations above 0.01%, though a product-specific compatibility study is required.

Wet granulation of the API is selected not for convenience but to reduce dust, improve flow into automatic oral dosing equipment, and minimize segregation of the fibrous component from denser excipients. A top-spray fluid bed process is used with a binder solution of hydroxypropyl methylcellulose at 2.0–4.0% w/w solids in purified water. The powder is fluidized at inlet air 55–65°C, and the product temperature is held between 35°C and 40°C to avoid thermal degradation of volatile oil markers. Spray rate for a 5 kg development batch is typically 10–20 g/min; scale-up to a 100 kg production bowl requires adjustment of the atomizing air ratio rather than a linear increase in spray rate. Final granule loss on drying is controlled at 2.0–3.0%, and the particle size is specified as not less than 80% retained on a 0.15 mm sieve and not more than 10% fines passing a 0.075 mm sieve. These granules are filled into sachets or bulk packs for oral top-dressing or direct administration to piglets and calves. The processing boundary is sharp: if the product temperature exceeds 40°C, diterpene and volatile fractions may be partially lost; if the inlet air is reduced below 50°C, drying time extends beyond 90 min, increasing the risk of caking in the filter bag. A lower-risk alternative is low-shear wet granulation in a plow mixer, but that route produces a wider particle size distribution and requires an additional 0.5 mm screening step.

What Filling Parameters Change When Botanical Powder Is Encapsulated?

Hard gelatin capsule filling of the milled botanical API requires moisture, particle size, and pin setting control that differ from direct powder compression. The powder is milled to pass a 0.3 mm sieve and dried to 4.0–5.0% moisture; moisture below 3.0% can embrittle hard gelatin capsules, while moisture above 6.0% softens the shell and accelerates crosslinking of gelatin during storage. A tamping-pin capsule filler is preferred over a dosator machine because fibrous powders compress unevenly in a dosator and can cause fill weight variability above 5.0%. For a size 0 capsule, the pin settings are adjusted to 3–5 tamping stations to achieve a fill weight up to 500 mg without crushing the granulation; size 00 is used when the dose exceeds that mass. The formulated powder may include 0.2–0.5% w/w colloidal silicon dioxide as a glidant; higher percentages can reduce powder hammering but may decrease dissolution of hydrophobic botanical resins. The terminal capsule product is intended for individual body-weight dosing of companion animals or calves, where tablets may be difficult to administer. If the capsule is intended for food-producing animals, the assigned withdrawal period must reflect the capsule formulation and the marker depletion profile, not the oral powder data alone.

Parenteral Use Requires an Extraction and Depyrogenation Sequence, Not Direct Reconstitution

Crude Huashi Zhixie Powder cannot be directly suspended or dissolved into an injectable dosage form; the powder contains plant fibres, lipopolysaccharides of microbial origin, and protein-polysaccharide complexes that are not acceptable in a parenteral product. If an injectable presentation is required for a specific veterinary indication, the development route is a multi-step botanical extract. A decoction is prepared in water for injection at 90–95°C for 30 min; the filtrate is concentrated under reduced pressure at 60°C or lower. Ethanol is added to a final concentration of 70% v/v to precipitate high-molecular-weight polysaccharides and proteins; the supernatant is separated and the ethanol removed under vacuum. The aqueous concentrate is then clarified by centrifugation at 10,000×g for 15 min, filtered through 0.45 µm and 0.22 µm membranes, and subjected to ultrafiltration through a 10 kDa MWCO membrane to reduce endotoxin load. The final filtrate is adjusted to pH 5.0–7.0 with a pharmacopoeial acid or buffer, and the solution is sterilized by terminal moist heat or aseptic filtration. Bacterial endotoxin is tested by USP <85>; the limit is calculated from the maximum intended bolus dose per kilogram body weight. For a parenteral limit of 5 EU/kg and a maximum dose of 1 mL/kg, the extract limit is 5 EU/mL, but the actual limit must be validated for the target species. Sterility is evaluated by USP <71>, and particulate matter is controlled by USP <788>. Published data for this specific powder’s injectable extract profile is limited; no injectable batch should be produced without a full extraction, marker recovery, pyrogen, and repeat-dose safety package. The extract may precipitate when compounded directly with normal saline due to high ionic strength; a 5% w/v glucose vehicle is often screened for compatibility after confirmation of chemical stability. Direct reconstitution of the powder in saline is outside compendial quality and must not be presented as an injectable preparation.

For oral powders intended for top-dressing onto feed or for oral drench after mixing with water, the primary specification is powder fineness and moisture-barrier packaging. The API is passed through a 0.25 mm sieve and blended with 0.2–0.5% w/w colloidal silicon dioxide to reduce caking during storage. The finished powder is packed in aluminium foil laminate pouches with a water vapour transmission rate below 0.5 g/m²/day at 38°C/90% RH, and the headspace is purged with nitrogen if long-term storage is planned. The direct oral powder is not appropriate for incorporation into pelleted feed through the high-temperature conditioner; if pelleted feed is required, the powder should be added post-pelleting or the pellet conditioning temperature reduced below 60°C to protect volatile marker compounds. Powder uniformity is tested by sampling not fewer than 5 units and assaying marker content; a release limit of 85.0–115.0% of label claim is typical for botanical oral powders. The powder should not be combined with strongly alkaline mineral premixes because the alkaline microclimate can accelerate hydrolysis of glycosidic components during storage.